Advertisement

Hyperkalemia

  • Ryann Sohaney
  • Michael HeungEmail author
Chapter
  • 9 Downloads

Abstract

Hyperkalemia is a potentially life-threatening condition that occurs commonly among the critically ill, most commonly in the setting of acute or chronic renal failure. Hyperkalemia can develop from a variety of mechanisms, and can even be spurious (pseudohyperkalemia). Therefore, the first step in management is to determine underlying causes. In severe cases, such as with ECG abnormalities, cardiac membrane stabilization is warranted with intravenous calcium. In addition, the fastest way to lower serum potassium is to induce intracellular potassium shifting. When total body potassium overload is present, therapies designed to promote either renal or gastrointestinal potassium removal are indicated, but take longer to have an impact (usually hours). Recently, newer potassium-binding agents have become available and may have a shorter time to effect. Hemodialysis is a highly effective option to lower hyperkalemia when medical management is ineffective.

Keywords

Hyperkalemia Potassium binders Arrhythmia Acute hemodialysis 

References

  1. 1.
    Finch CA, Sawyer CG, Flynn JM. Clinical syndrome of potassium intoxication. Am J Med. 1946;1:337–52.CrossRefGoogle Scholar
  2. 2.
    Colussi G, Cipriani D. Pseudohyperkalemia in extreme leukocytosis. Am J Nephrol. 1995;15:450–2.CrossRefGoogle Scholar
  3. 3.
    Clausen T. Adrenergic control of Na+-K+-homoeostasis. Acta Medica Scand Suppl. 1983;672:111–5.Google Scholar
  4. 4.
    Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int. 1990;38:301–7.CrossRefGoogle Scholar
  5. 5.
    Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol. 2011;22:1981–9.CrossRefGoogle Scholar
  6. 6.
    Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050–60.CrossRefGoogle Scholar
  7. 7.
    Batlle D, Arruda J. Hyperkalemic forms of renal tubular acidosis: clinical and pathophysiological aspects. Adv Chronic Kidney Dis. 2018;25:321–33.CrossRefGoogle Scholar
  8. 8.
    Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10:e004667.CrossRefGoogle Scholar
  9. 9.
    Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75:554–6.CrossRefGoogle Scholar
  10. 10.
    Montoliu J, Lens XM, Revert L. Potassium-lowering effect of albuterol for hyperkalemia in renal failure. Arch Intern Med. 1987;147:713–7.CrossRefGoogle Scholar
  11. 11.
    Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989;110:426–9.CrossRefGoogle Scholar
  12. 12.
    Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38:869–72.CrossRefGoogle Scholar
  13. 13.
    Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. Clin Nephrol. 2016;85:38–43.CrossRefGoogle Scholar
  14. 14.
    Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery. 1987;101:267–72.PubMedGoogle Scholar
  15. 15.
    Hunt TVDJ, Ackerbauer KA, Whittier WL, Peksa GD. Singel-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease. Clin Kidney J. 2018;12:408–13.  https://doi.org/10.1093/ckj/sfy063.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151–61.CrossRefGoogle Scholar
  17. 17.
    Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88:1427–33.CrossRefGoogle Scholar
  18. 18.
    Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222–31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Nephrology, Department of MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations